Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 6/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | NNMT | P40261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30151419 | 0.86 | KDM4E (0.52) | CSNK1A1CLK4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL840684 | 0.86 | KDM4E (0.52) | CSNK1A1CLK4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30068026 | 0.76 | TLR8 (0.45) | CSNK1A1CLK4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL25323208 | 0.76 | TLR8 (0.45) | CSNK1A1CLK4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL26627840 | 0.74 | TLR8 (0.44) | CSNK1A1CLK4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL16685657 | 0.70 | CSNK1A1 (0.42) | CSNK1A1CLK4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL25902427 | 0.70 | CSNK1A1 (0.42) | CSNK1A1CLK4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL26627777 | 0.70 | CSNK1A1 (0.46) | CSNK1A1CLK4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30462039 | 0.70 | CSNK1A1 (0.46) | CSNK1A1CLK4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL28557324 | 0.69 | ALDH1A1 (0.38) | KDM4EALDH1A1SMN1; SMN2PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | CSNK1A1 180/4885CLK4 1335/4885KDM4E 958/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | CSNK1A1 180/4885CLK4 1335/4885KDM4E 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.